Markets
markets
Luke Kawa

ServiceNow strikes deal to buy cybersecurity firm Armis for $7.75 billion in cash

ServiceNow has agreed to acquire cybersecurity startup Armis for $7.75 billion in an all-cash deal, the largest purchase in the companys history.

That price tag is $750 million above what Bloomberg suggested was the top end of what Armis would cost just last week, and about $1.65 billion above what the company had been valued at in a November funding round.

Armis had been readying itself for an IPO, with many major investors looking to take a stake in the firm.

Instead, it’s now a key cog in the software platform company’s bid to lean on cybersecurity features to bolster its appeal to customers in a world where the rise of AI adds to the potential threats of business disruptions and data breaches.

Per the press release:

As rapid AI adoption expands the attack surface for organizations, real-time visibility into vulnerabilities and actionable insights for what to fix first are critical to minimize risk and strengthen security posture. The acquisition of Armis will extend and enhance ServiceNow’s Security, Risk, and OT portfolios in critical and fast-growing areas of cybersecurity and drive increased AI adoption by strengthening trust across businesses’ connected environments.

More Markets

See all Markets
markets

Tesla delivered 358,023 vehicles in Q1, short of expectations

Ahead of its first-quarter earnings later this month, Tesla on Thursday announced that it delivered 358,023 vehicles in the quarter.

Analysts polled by FactSet had expected 380,500 vehicle deliveries in the first quarter this year, while Tesla last month released its own company-compiled Wall Street consensus estimate — something it began in the fourth quarter of 2025 — of 365,645 vehicles.

Shares extended losses in premarket trading on Thursday, falling more than 4%.

The figure is still up from the same quarter last year, when Tesla delivered fewer than 337,000 vehicles amid intensifying competition in China and flailing public perception over CEO Elon Musk’s involvement with the Trump administration.

As of 3 p.m. ET on Wednesday, event contract odds held a slightly less optimistic view than the broader analyst community, but a sunnier view than the figure Tesla put forward. 52% of traders predicted Tesla’s Q1 deliveries would come in at more than 360,000, 40% thought the figure would be higher than 370,000, and 15% estimated it would be higher than 380,000.

(Event contracts are offered through Robinhood Derivatives, LLC — probabilities referenced or sourced from KalshiEx LLC or ForecastEx LLC.)

markets

Globalstar surges after FT reports that Amazon is in talks to buy the satellite group

Globalstar is up 11% in premarket trading on Thursday on reports that Amazon is in talks to buy the satellite company, in a push to take on Elon Musks SpaceX. The two companies are currently negotiating the details of a potential deal after lengthy talks, the Financial Times reported, citing people familiar with the matter.

Amazon has ambitions to compete with SpaceX to provide satellite-based internet access anywhere on the planet — a market thats dominated by Starlink at the moment and a key pillar of the eye-watering $1 trillion valuation that SpaceX is seeking in its IPO, which it has just confidentially filed for.

Indeed, Amazon has been signing deals with airlines and doubling down on investing in its internet constellation lately, with plans to increase its ~200 satellites in orbit to about 700 by the middle of 2026 — still a fraction compared to SpaceX’s mega constellation, which has some 10,000 active satellites.

But Amazon’s not the only Big Tech giant with an interest in Globalstar. Back in 2024, Apple invested $1.5 billion for a 20% stake in the company, necessitating a negotiation between Apple and Amazon for the latest deal talks to proceed, per the FT. SpaceX also reportedly had early talks with Globalstar, Bloomberg reported last October.

Globalstars stock has been up ~230% in the past year, pushing its value to some $8.8 billion as of yesterday’s close.

Amazon has ambitions to compete with SpaceX to provide satellite-based internet access anywhere on the planet — a market thats dominated by Starlink at the moment and a key pillar of the eye-watering $1 trillion valuation that SpaceX is seeking in its IPO, which it has just confidentially filed for.

Indeed, Amazon has been signing deals with airlines and doubling down on investing in its internet constellation lately, with plans to increase its ~200 satellites in orbit to about 700 by the middle of 2026 — still a fraction compared to SpaceX’s mega constellation, which has some 10,000 active satellites.

But Amazon’s not the only Big Tech giant with an interest in Globalstar. Back in 2024, Apple invested $1.5 billion for a 20% stake in the company, necessitating a negotiation between Apple and Amazon for the latest deal talks to proceed, per the FT. SpaceX also reportedly had early talks with Globalstar, Bloomberg reported last October.

Globalstars stock has been up ~230% in the past year, pushing its value to some $8.8 billion as of yesterday’s close.

markets

FDA clarifies stricter stance on GLP-1 compounding: Reuters

The Food and Drug Administration reiterated its increasingly strict stance on compounded versions of GLP-1s, Reuters reported Wednesday.

The FDA said that outside of drug shortages, “routine production” of copycat drugs is not allowed. Producing the compounded versions could now “prompt enforcement action,” Reuters reported.

Hims & Hers, which has historically been one of the largest sellers of copycat GLP-1s, fell more than 4% on Wednesday and slipped further in premarket trading on Thursday.

Hims attracted FDA scrutiny in February when it launched a copy of Novo Nordisk’s new GLP-1 pill. At the time, the FDA said it would take “decisive steps” to restrict GLP-1 compounding in a statement that specifically called out Hims.

After a bitter spat with Novo, which makes Ozempic and Wegovy, Hims entered a pact with the drugmaker in which it agreed not to market compounded GLP-1s.

Hims & Hers, which has historically been one of the largest sellers of copycat GLP-1s, fell more than 4% on Wednesday and slipped further in premarket trading on Thursday.

Hims attracted FDA scrutiny in February when it launched a copy of Novo Nordisk’s new GLP-1 pill. At the time, the FDA said it would take “decisive steps” to restrict GLP-1 compounding in a statement that specifically called out Hims.

After a bitter spat with Novo, which makes Ozempic and Wegovy, Hims entered a pact with the drugmaker in which it agreed not to market compounded GLP-1s.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.